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A cDNA clone of the bovine immunodeficiency-like virus (BW) trans-activator gene (tat) was identified and 
characterized. The tat cDNA clone was generated by splicing, and on the basis of sequence analysis, the Tat 
protein was found to be encoded entirely by the first exon. It is 103 amino acids in size and shares sequence 
homology with the human immunodeficiency virus (HW) Tat. The BIV tat clone can trans activate the BIV 
promoter effectively, as measured by the expression of the bacterial chloramphenicol acetyltransferase gene, 
when transfected into bovine cells. Besides activating the BIV promoter, the BIV Tat can also trans activate the 
HIV promoter effectively. It is possible that BIV Tat and HIV Tat employ similar mechanisms in trans 
activation of the viral long terminal repeat-directed gene expression. 
Bovine immunodeficiency-like virus (BIV) is a recently 
characterized bovine lentivirus which causes lymphadenop- 
athy, lymphocytosis, and central nervous system disorders 
in infected cattle (3, 22). The virus has been cloned, and the 
nucleotide sequence of the BIV genome has been deter- 
mined (4, 10). The genome is approximately 9.0 kb in size 
and contains the structural genes gag, pol, and env, as well 
as other open reading frames analogous to the vif, tat, and 
rev genes of human immunodeficiency virus (HIV) (6,7,10). 
The HIV tat gene is an important regulatory gene (6, 8). 
Several studies have shown that HIV Tat increases the 
steady-state level of HIV mRNA in part by increasing the 
rate of transcription initiation (14, 15) and the efficiency of 
transcription elongation (12). It has been demonstrated re- 
cently that BIV-infected cells also express a trans-acting 
protein, similar to the HIV Tat (18). However, the tat gene 
of BIV has not been identified, and its trans-activation 
function has not been demonstrated. Analysis of the BIV 
transcriptional pattern by Northern (RNA) blot indicated 
that multiple transcripts were expressed, and several subge- 
nomic viral RNAs that can potentially encode the BIV Rev 
and Tat proteins were detected (17). In order to specifically 
identify and characterize the BIV tat gene, we used poly- 
merase chain reaction to amplify viral mRNAs that can 
potentially encode the Tat protein. 
Cloning of BIV tat by polymerase chain reaction. On the 
basis of the BIV genomic sequence analyses (lo), it was 
predicted that BIV tat is encoded by two exons (Fig. 1A). 
The first is encoded by an exon 5' of the envelope gene from 
nucleotides (nt) 5228 to 5536, and the second is encoded by 
an exon located within the envelope gene from nt 7657 to 
7782. In order to clone both tat exons, three different 
primers were used to amplify BIV-infected embryonic bo- 
vine lung (EBL) cell mRNA. The first primer, PT1, should 
prime 5' to the first predicted tat exon, and the second 
primer, PT2, should prime 3' of the predicted second exon 
(Fig. 1B). The third primer, PT3, was also used in place of 
PT2 to prime at the poly(A) tail located at the 3' end of tat 
mRNA. Several clones were generated by either the first 
(PT1 and PT2) or the second (PT1 and PT3) set of primers. 
One clone generated from the first primer set (TATC-1) and 
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one clone from the second primer set (TATC-2) were further 
mapped and characterized. They were found to be very 
similar. Both cany exons 1 and 2 of the putative tat gene 
(Fig. 1C). The TATC-1 insert is smaller and terminates at the 
end of the second tat exon at nt 7787, where the PT2 primer 
binds. The TATC-2 clone is larger, and its second exon 
extends to the 3' end of the BIV genome, all the way to the 
polyadenylation site at nt 8485. The nucleotide sequence of 
TATC-1, its deduced amino acid sequence, and a compari- 
son with a previously published BIV genomic sequence (10) 
are shown in Fig. 2. The sequence of our cDNA clone 
TATC-1 is very similar to the published genomic clone 
sequence: there are only three nucleotide differences be- 
tween the two sequences, and two of these changes led to 
amino acid substitutions. Our cDNA sequence also indicates 
that the splice junction between tat exons 1 and 2 is different 
from the one predicted earlier (10). Our sequence indicates 
that the splice donor and acceptor sites for tat exon 2 are 
located at nt 5541 and 7638, respectively, whereas the 
previously predicted locations were at nt 5536 and 7657 (Fig. 
1 and 2). Interestingly, the splice junction for tat is identical 
to that previously mapped for the BIV rev gene (17). In 
addition, our cDNA clone has three in-frame stop codons: 
one can be found before the splice junction, and the other 
two are in the second exon immediately after the splice 
junction. This suggests that the second exon may not encode 
any Tat protein sequence and that the 103-amino-acid (103- 
aa) Tat protein is encoded entirely within the first exon. 
The translated TATC-1 sequence displays several com- 
mon features that are found in other lentiviral Tat proteins 
(5). There is a cysteine-rich domain (aa 38 to 46) containing 
a cluster of five cysteines. Mutations of these analogous 
cysteine residues in HIV can abolish Tat function completely 
(13). There is also a core region of BIV Tat, HCQLCF 
LQ-KNBL NYY (aa 49 to 64), which bears striking homology 
to the HIV core region, HCQVCFTI'KALGISYG (aa 33 to 48). 
Alignment of the HIV-1 and BIV Tat sequences indeed shows 
a 54% amino acid homology within their cysteine-rich and core 
regions; both regions are essential for HIV-1 Tat protein to 
function in tram activation (5). In the BIV Tat protein, there 
also exists a basic domain, RGKGRRIRR (aa 73 to 81), which 
bears some homology to the domain (RKKRRQRRR) found in 
HIV-1 (19). This domain was predicted to be the nuclear 
localization motif for HIV. Further experiments are required to 
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FIG. 1. (A) Schematic representation of organization of the BIV 
genome. The predicted B N  tat exon 1 is indicated by the solid box, 
and exon 2 is indicated by the slashed box. Numbers indicate the 
predicted nucleotide positions of the tat exons (10). (B) Locations of 
primers used for cloning tat cDNA and the BIV LTR. The primers 
are as follows: PL1, 5'-CGCCACGCTCCTATTlTA-3' (nt 7953 to 
7970), which is located in the 5' end of the U3 region of the LTR; 
PL2, 5'-CCGAGCCAGTGCCTCTC-3' (nt 8435 to 8419, an an- 
tisense primer), which is located in the R region of the LTR; PT1, 
5'-CAlTCATAGAlTGTGGCA-3' (nt 5208 to 5225), which is lo- 
cated before the predicted tat exon 1; PT2, 5'-GlTCAACCAAT 
TCTCGTAGA-3' (nt 7787 to 7768, an antisense primer), which 
spans the predicted stop codon of tat exon 2; and PT3, 5'-lTGTC 
GA--3', which is an oligo(dT) primer wn- 
taining a SalI recognition site at the 5' end. PCR, polymerase chain 
reaction. (C) Schematic representation of the two tat cDNA clones 
obtained with primers PT1 and PT2 (TATC-1) and with primers PT1 
and PT3 (TATC-2). Numbers indicate the nucleotide positions and 
the location of the splice junction between tat exons 1 and 2. R, R 
region. 
demonstrate the functions of these domains in the BIV Tat 
protein. 
The &af cDNA clone can trans activate the BlV promoter. To 
test whether our tat cDNA clone can trans activate BIV long 
terminal repeat (LTR) expression, a BIV-CAT construct 
which contains the chloramphenicol acetyltransferase (CAT) 
gene under the control of the BIV LTR was made. Our tat 
cDNA clone TATC-2 was also cloned into a plasmid under 
the control of the simian virus 40 promoter to generate the 
tat expression vector pBTATC. This clone was then cotrans- 
fected into EBL cells along with the BIV-CAT plasmid to 
check for trans activation of CAT expression. In the pres- 
ence of pBTATC, BIV-CAT was activated and resulted in a 
20-fold increase in CAT activity (Table 1). Since the putative 
Tat protein is encoded entirely by the first exon, our results 
suggest that exon 1 alone is sufficient for trans activation of 
the BIV LTR. To further confirm that a functional BIV Tat 
protein can be entirely encoded by only one exon, a second 
BIV-tat clone was generated from the genomic BIV clone 
(1). This plasmid, pBTATG, was constructed by inserting 
the BIV proviral DNA fragment containing an intact proviral 
5' LTR and the predicted tat exon 1 into a pUC18 vector. 
This genomic clone thus lacks the second tat exon and the 3' 
end of the BIV genome. When pBTATG was cotransfected 
into EBL cells along with BIV-CAT, trans activation of the 
BIV LTR-directed CAT expression was observed. There 
was a 25-fold increase of CAT activity in the presence of 
pBTATG (Table 1). Interestingly, the genomic pBTATG 
clone consistently yields slightly higher levels of trans-acting 
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FIG. 2. Nucleotide sequence and translated amino acid sequence 
of BIV tat cDNA clone TATC-1. Nucleotide numbers are given at 
the top, and the amino acid numbers are given on the side. The 
TATC-1 sequence (top sequence) and the published BIV tat ge- 
nomic sequence (10) (bottom sequence) are shown. The dashed line 
represents sequence identity between TATC-1 and the published 
genomic sequence, and the differences in the sequences are indi- 
cated. The arrow between nt 314 and 315 represents the splice 
junction between tat exons 1 and 2; < > represents the predicted 
splice donor and acceptor sites (10). Termination wdons are also 
indicated (boldface). 
activity than our tat cDNA clone, pBTATC. It is possible 
that pBTATG, which uses the BIV LTR as a promoter, is 
more effective in expressing tat mRNA, and the Tat protein 
produced may in turn provide positive feedback to further 
trans activate the BIV LTR. 
BIV Tat is similar to HlV Tat and can trans activate the HIV 
LTR. Since the BIV Tat protein sequence shares some 
homology with the HIV-1 Tat core and cysteine-rich regions 
(19), it would be of interest to test whether BIV Tat could 
trans activate the HIV LTR and vice versa. EBL cells were 
either transfected with HIV-CAT (11) alone or cotransfected 
with the BIV tat cDNA clone pBTATC or genomic clone 
pBTATG. The results in Table 1 show that the HIV LTR can 
indeed be trans activated by BIV Tat and that the presence 
of pBTATC or pBTATG elevated HIV LTR-directed CAT 
gene expression by approximately 8- and 18-fold, respec- 
tively. Even though this level of trans activation is signifi- 
cant, it is still lower than the previously observed 50- to 
100-fold activation of the HIV LTR by its homologous HIV 
tat gene product. In bovine cells, the lower level of activa- 
tion of the HIV LTR by BIV Tat cannot be due to the 
absence of appropriate cellular factors, since the HIV LTR 
can be activated by HIV Tat by approximately 101-fold in 
these cells (Table 1). Thus, the lower level of trans activation 
of the HIV LTR by BIV Tat may simply reflect structural 
differences between HIV and BIV Tat proteins. The trans 
activation of HIV-CAT by BIV Tat is specific; other viral 
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TABLE 1. trans activation of CAT promoter constructs by 
different tat plasmids0 
Construct and CAT enzyme activity Fold 
plasmid (cpm.lO6 cells)b activation 
BIV-CAT 
None 
pBTATC 
pBTATG 
HIV TAT 
HIV-CAT 
None 
pBTATC 
pBTATG 
HIV TAT 
ABIV-CAT 
None 
pBTATC 
pBTATG 
pSV,-CAT 
None 
pBTATC 
HTLV-I-CAT 
None 
pBTATC 
a EBL cells were transfected with 2 pg of CAT plasmid and 10 pg of tat 
plasmid by the standard calcium phosphate precipitation procedures (2). 
Transfected cells were harvested at 48 h for CAT analyses. AU samples were 
corrected for protein concentration variations before they were assayed. 
Procedures for CAT assays with ['H]acetyl coenzyme A were described 
previously (16). 
The amount of CAT enzyme activity per lo6 transfected cells was 
measured over a 5-h period, and the values were calculated by taking the slope 
of the linear portion of the curve and expressed as counts per minute 
incorporated over a 1-h period. 
promoters, such as the human T-cell leukemia virus type I 
promoter construct (HTLV-I-CAT) or the simian virus 40 
viral promoter construct (pSV,-CAT), cannot be trans acti- 
vated by BIV Tat (Table 1). In addition, the BIV LTR can 
also be trans activated when cotransfected into EBL cells 
with the heterologous HIV tat expression plasmid (Table 1) 
(11). However, the activation of the BIV LTR by HIV-1 Tat 
is only about threefold and is much lower than the observed 
20- to 25-fold activation by BIV Tat. Nevertheless, this 
suggests that trans activation by the BIV Tat protein may 
involve mechanisms similar to those of HIV Tat. 
Z'hm activation of a deletion BIV LTR construct by BIV 
Tat. The trans-activation target of HIV Tat has been well 
characterized and is located downstream of the transcription 
initiation site (9, 20). Similarly, the Tat responding element 
for equine infectious anemia virus is also located within the 
LTR (21). Since BIV and HIV Tat proteins may use similar 
mechanisms in activation of their respective LTRs, it was of 
interest to determine whether the target site of BIV Tat is 
also located within the LTR. In order to test for the presence 
of the BIV Tat responding element, a BIV LTR deletion 
clone was tested. This clone, ABIV-CAT, was generated by 
using polymerase chain reaction primers to specifically am- 
plify the BIV LTR from the U3 region, up to position +64 in 
the R region, with respect to the mRNA start site. The 
amplified, deleted LTR was then cloned in front of the CAT 
gene to study LTR-directed CAT expression. When ABIV- 
CAT was cotransfected into EBL cells along with the 
pBTATC or pBTATG plasmid, even though activations of 
ABIV-CAT were still observed, the levels of trans activation 
were much lower (Table 1). Levels of activation of ABIV- 
CAT by pBTATC and pBTATG were about six- and three- 
fold lower than those of intact BIV-CAT, respectively. Our 
results suggest that the deletion in ABIV-CAT has removed 
part of the cis-acting target element which may be involved 
in the Tat-directed trans activation. 
Our study provides further evidence to support the idea 
that there are similarities between BIV and other lentivi- 
ruses, such as HIV. Not only are there similarities in 
genomic organization, nucleotide sequence (lo), and antige- 
nicities (I), but the BIV Tat is also very similar to that of 
HIV, as we have now demonstrated. These proteins appear 
to function through similar mechanisms. Further elucidation 
of the mechanism of Tat-mediated stimulation of BIV viral 
gene expression will require detailed mutagenesis studies of 
the functional domains of the BIV Tat protein and its 
cis-acting trans-activation target element, as well as studies 
to identify other cellular proteins that may be involved. 
Nucleotide sequence accession number. The GenBank nu- 
cleotide sequence accession number for the BIV tat gene is 
M90681. 
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